Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: Utility for detection of diverse HIV-1 subtypes

Surender Khurana, James Needham, Susan Park, Bonnie Mathieson, Michael P. Busch, George Nemo, Phillipe Nyambi, Susan Zolla-Pazner, Suman Laal, Joseph Mulenga, Elwyn Chomba, Eric Hunter, Susan Allen, James McIntyre, Indira Hewlett, Sherwin Lee, Shixing Tang, Elliot Cowan, Christopher Beyrer, Marcus AltfeldXu G. Yu, Anatole Tounkara, Ousmane Koita, Anatoli Kamali, Nga Nguyen, Barney S. Graham, Deborah Todd, Peter Mugenyi, Omu Anzala, Eduard Sanders, Nzeera Ketter, Patricia Fast, Hana Golding

Research output: Contribution to journalArticle

Abstract

Because increasing numbers of HIV vaccine candidates are being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Most of the currently tested vaccines contain multiple viral components. As a result, many vaccine recipients give positive results in FDA-licensed HIV serodetection tests. We have identified conserved sequences in Env-gp41 and Gag-p6, which are recognized soon after infection but are not included in most HIV vaccine candidates. A new HIV serodetection assay, the HIV-SELECTEST, was established that distinguishes between vaccine-induced antibodies and seroconversion due to true HIV infections. It is important to make this assay globally relevant, because many clinical trials are conducted around the world where most HIV infections are due to non-B subtype HIV-1. Therefore, the current study examined the reactivity of plasma samples from >3000 infections with diverse HIV subtypes worldwide. The HIV-SELECTEST performed at >99% specificity and sensitivity. Both recent and established infections with clades A, B, C, D, E, F, G, J, and CRFs were detected. Antibodies elicited by other vaccinations or infections endemic to the clinical trial sites did not react in this assay. Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide.

Original languageEnglish (US)
Pages (from-to)304-312
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume43
Issue number3
DOIs
StatePublished - Nov 2006

Fingerprint

HIV Infections
HIV-1
Differential Diagnosis
Vaccines
HIV
AIDS Vaccines
Antibodies
Infection
Clinical Trials
Viral Structures
Blood Banks
Conserved Sequence
Vaccination
Viruses
Sensitivity and Specificity
Population

Keywords

  • AIDS
  • Clinical trials
  • Diagnosis
  • Epitope mapping
  • HIV
  • Peptides
  • Phage display
  • Vaccine

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies : Utility for detection of diverse HIV-1 subtypes. / Khurana, Surender; Needham, James; Park, Susan; Mathieson, Bonnie; Busch, Michael P.; Nemo, George; Nyambi, Phillipe; Zolla-Pazner, Susan; Laal, Suman; Mulenga, Joseph; Chomba, Elwyn; Hunter, Eric; Allen, Susan; McIntyre, James; Hewlett, Indira; Lee, Sherwin; Tang, Shixing; Cowan, Elliot; Beyrer, Christopher; Altfeld, Marcus; Yu, Xu G.; Tounkara, Anatole; Koita, Ousmane; Kamali, Anatoli; Nguyen, Nga; Graham, Barney S.; Todd, Deborah; Mugenyi, Peter; Anzala, Omu; Sanders, Eduard; Ketter, Nzeera; Fast, Patricia; Golding, Hana.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 43, No. 3, 11.2006, p. 304-312.

Research output: Contribution to journalArticle

Khurana, S, Needham, J, Park, S, Mathieson, B, Busch, MP, Nemo, G, Nyambi, P, Zolla-Pazner, S, Laal, S, Mulenga, J, Chomba, E, Hunter, E, Allen, S, McIntyre, J, Hewlett, I, Lee, S, Tang, S, Cowan, E, Beyrer, C, Altfeld, M, Yu, XG, Tounkara, A, Koita, O, Kamali, A, Nguyen, N, Graham, BS, Todd, D, Mugenyi, P, Anzala, O, Sanders, E, Ketter, N, Fast, P & Golding, H 2006, 'Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: Utility for detection of diverse HIV-1 subtypes', Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 3, pp. 304-312. https://doi.org/10.1097/01.qai.0000242465.50947.5f
Khurana, Surender ; Needham, James ; Park, Susan ; Mathieson, Bonnie ; Busch, Michael P. ; Nemo, George ; Nyambi, Phillipe ; Zolla-Pazner, Susan ; Laal, Suman ; Mulenga, Joseph ; Chomba, Elwyn ; Hunter, Eric ; Allen, Susan ; McIntyre, James ; Hewlett, Indira ; Lee, Sherwin ; Tang, Shixing ; Cowan, Elliot ; Beyrer, Christopher ; Altfeld, Marcus ; Yu, Xu G. ; Tounkara, Anatole ; Koita, Ousmane ; Kamali, Anatoli ; Nguyen, Nga ; Graham, Barney S. ; Todd, Deborah ; Mugenyi, Peter ; Anzala, Omu ; Sanders, Eduard ; Ketter, Nzeera ; Fast, Patricia ; Golding, Hana. / Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies : Utility for detection of diverse HIV-1 subtypes. In: Journal of Acquired Immune Deficiency Syndromes. 2006 ; Vol. 43, No. 3. pp. 304-312.
@article{8501741f59494d94ab7d710f7d1142ee,
title = "Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: Utility for detection of diverse HIV-1 subtypes",
abstract = "Because increasing numbers of HIV vaccine candidates are being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Most of the currently tested vaccines contain multiple viral components. As a result, many vaccine recipients give positive results in FDA-licensed HIV serodetection tests. We have identified conserved sequences in Env-gp41 and Gag-p6, which are recognized soon after infection but are not included in most HIV vaccine candidates. A new HIV serodetection assay, the HIV-SELECTEST, was established that distinguishes between vaccine-induced antibodies and seroconversion due to true HIV infections. It is important to make this assay globally relevant, because many clinical trials are conducted around the world where most HIV infections are due to non-B subtype HIV-1. Therefore, the current study examined the reactivity of plasma samples from >3000 infections with diverse HIV subtypes worldwide. The HIV-SELECTEST performed at >99{\%} specificity and sensitivity. Both recent and established infections with clades A, B, C, D, E, F, G, J, and CRFs were detected. Antibodies elicited by other vaccinations or infections endemic to the clinical trial sites did not react in this assay. Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide.",
keywords = "AIDS, Clinical trials, Diagnosis, Epitope mapping, HIV, Peptides, Phage display, Vaccine",
author = "Surender Khurana and James Needham and Susan Park and Bonnie Mathieson and Busch, {Michael P.} and George Nemo and Phillipe Nyambi and Susan Zolla-Pazner and Suman Laal and Joseph Mulenga and Elwyn Chomba and Eric Hunter and Susan Allen and James McIntyre and Indira Hewlett and Sherwin Lee and Shixing Tang and Elliot Cowan and Christopher Beyrer and Marcus Altfeld and Yu, {Xu G.} and Anatole Tounkara and Ousmane Koita and Anatoli Kamali and Nga Nguyen and Graham, {Barney S.} and Deborah Todd and Peter Mugenyi and Omu Anzala and Eduard Sanders and Nzeera Ketter and Patricia Fast and Hana Golding",
year = "2006",
month = "11",
doi = "10.1097/01.qai.0000242465.50947.5f",
language = "English (US)",
volume = "43",
pages = "304--312",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies

T2 - Utility for detection of diverse HIV-1 subtypes

AU - Khurana, Surender

AU - Needham, James

AU - Park, Susan

AU - Mathieson, Bonnie

AU - Busch, Michael P.

AU - Nemo, George

AU - Nyambi, Phillipe

AU - Zolla-Pazner, Susan

AU - Laal, Suman

AU - Mulenga, Joseph

AU - Chomba, Elwyn

AU - Hunter, Eric

AU - Allen, Susan

AU - McIntyre, James

AU - Hewlett, Indira

AU - Lee, Sherwin

AU - Tang, Shixing

AU - Cowan, Elliot

AU - Beyrer, Christopher

AU - Altfeld, Marcus

AU - Yu, Xu G.

AU - Tounkara, Anatole

AU - Koita, Ousmane

AU - Kamali, Anatoli

AU - Nguyen, Nga

AU - Graham, Barney S.

AU - Todd, Deborah

AU - Mugenyi, Peter

AU - Anzala, Omu

AU - Sanders, Eduard

AU - Ketter, Nzeera

AU - Fast, Patricia

AU - Golding, Hana

PY - 2006/11

Y1 - 2006/11

N2 - Because increasing numbers of HIV vaccine candidates are being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Most of the currently tested vaccines contain multiple viral components. As a result, many vaccine recipients give positive results in FDA-licensed HIV serodetection tests. We have identified conserved sequences in Env-gp41 and Gag-p6, which are recognized soon after infection but are not included in most HIV vaccine candidates. A new HIV serodetection assay, the HIV-SELECTEST, was established that distinguishes between vaccine-induced antibodies and seroconversion due to true HIV infections. It is important to make this assay globally relevant, because many clinical trials are conducted around the world where most HIV infections are due to non-B subtype HIV-1. Therefore, the current study examined the reactivity of plasma samples from >3000 infections with diverse HIV subtypes worldwide. The HIV-SELECTEST performed at >99% specificity and sensitivity. Both recent and established infections with clades A, B, C, D, E, F, G, J, and CRFs were detected. Antibodies elicited by other vaccinations or infections endemic to the clinical trial sites did not react in this assay. Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide.

AB - Because increasing numbers of HIV vaccine candidates are being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Most of the currently tested vaccines contain multiple viral components. As a result, many vaccine recipients give positive results in FDA-licensed HIV serodetection tests. We have identified conserved sequences in Env-gp41 and Gag-p6, which are recognized soon after infection but are not included in most HIV vaccine candidates. A new HIV serodetection assay, the HIV-SELECTEST, was established that distinguishes between vaccine-induced antibodies and seroconversion due to true HIV infections. It is important to make this assay globally relevant, because many clinical trials are conducted around the world where most HIV infections are due to non-B subtype HIV-1. Therefore, the current study examined the reactivity of plasma samples from >3000 infections with diverse HIV subtypes worldwide. The HIV-SELECTEST performed at >99% specificity and sensitivity. Both recent and established infections with clades A, B, C, D, E, F, G, J, and CRFs were detected. Antibodies elicited by other vaccinations or infections endemic to the clinical trial sites did not react in this assay. Therefore, HIV-SELECTEST could be an important differential diagnostic tool for HIV vaccine trials, blood banks, and population screening worldwide.

KW - AIDS

KW - Clinical trials

KW - Diagnosis

KW - Epitope mapping

KW - HIV

KW - Peptides

KW - Phage display

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=33750569606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750569606&partnerID=8YFLogxK

U2 - 10.1097/01.qai.0000242465.50947.5f

DO - 10.1097/01.qai.0000242465.50947.5f

M3 - Article

C2 - 17019363

AN - SCOPUS:33750569606

VL - 43

SP - 304

EP - 312

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -